Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy

W Winnie Fernando J Jarama Clucas A Alberto Rizzo R Ramsay Singer E Emily Goode C Crescens Tiu S Scott Layzell J Joshua Konecnik R Rebecca Wilson S Sidonie Wicky John S Samuel Jouny N Naomi Guppy V Victoire Boulat J Jonathan Mannion M Maria Goicoechea S Shaun Tan (Department of Chemistry) S Sam Lawson C Chris Starling G Gabrielle Elshtein N Nivedita Ravindran A Anna B. Montgomery R Rosa Andres-Ejarque M Mark Allen S Steven Lumbard F Fredrik Wallberg K Kai Betteridge R Ross Scrimgeour D David Robertson G George Ward M Martin Sims T Tomoko Smyth A Andre L. Samson J James M. Murphy D Daniela Kolarevic Ivankovic E Esther N. Arwert D Dinis P. Calado A Anita Grigoriadis M Matthew J. Smalley A Alan Melcher S Syed Haider T Toby Lawrence I Ioannis Roxanis A Andrew N. J. Tutt T Tencho Tenev P Pascal Meier

Abstract

Abstract Immunotherapy has transformed cancer treatment, including early triple-negative breast cancer (TNBC), yet most patients with advanced TNBC fail to respond to immune checkpoint blockade (ICB) plus chemotherapy. Durable control likely requires not only tumour cell killing but also immunogenic cell death (ICD) that activates antitumour immunity. Using a Brca1 ⁻/⁻ p53 ⁻/⁻ organoid-derived TNBC model that recapitulates the immune landscapes of basal-like tumours, we show that RIPK1-driven ICD synergises with anti-PD-1 therapy to induce durable tumour control and immune memory in immune-infiltrated tumours. Mechanistically, both tumour-intrinsic and stromal necroptosis are required. Deletion of Ripk1 or Mlkl in tumour cells, or Mlkl in the stromal compartment, markedly impairs therapeutic efficacy. Moreover, immunologically “cold” tumours can be rendered responsive to ICD-based therapy by STING agonists. These findings demonstrate that the benefit of IAP antagonism with checkpoint blockade critically depends on coordinated necroptosis in both tumour and stromal cells, underscoring the need to integrate tumour microenvironmental context when designing ICD-targeted immunotherapies.

Article Details

Volume / Issue Vol. 17, Issue 1
Published March 06, 2026
ISSN 2041-1723
Publisher Nature Portfolio

Journal Info

Nature Communications

Nature Portfolio

ISSN: 2041-1723 Open Access Life Sciences

Authors (45)

W

Winnie Fernando

J

Jarama Clucas

A

Alberto Rizzo

R

Ramsay Singer

E

Emily Goode

C

Crescens Tiu

S

Scott Layzell

J

Joshua Konecnik

R

Rebecca Wilson

S

Sidonie Wicky John

S

Samuel Jouny

N

Naomi Guppy

V

Victoire Boulat

J

Jonathan Mannion

M

Maria Goicoechea

S

Shaun Tan

Department of Chemistry

S

Sam Lawson

C

Chris Starling

G

Gabrielle Elshtein

N

Nivedita Ravindran

A

Anna B. Montgomery

R

Rosa Andres-Ejarque

M

Mark Allen

S

Steven Lumbard

F

Fredrik Wallberg

K

Kai Betteridge

R

Ross Scrimgeour

D

David Robertson

G

George Ward

M

Martin Sims

T

Tomoko Smyth

A

Andre L. Samson

J

James M. Murphy

D

Daniela Kolarevic Ivankovic

E

Esther N. Arwert

D

Dinis P. Calado

A

Anita Grigoriadis

M

Matthew J. Smalley

A

Alan Melcher

S

Syed Haider

T

Toby Lawrence

I

Ioannis Roxanis

A

Andrew N. J. Tutt

T

Tencho Tenev

P

Pascal Meier